Despite the transformative impact of ICIs on NSCLC treatment, EGFR mutations are consistently associated with diminished clinical benefit, and in some cases, even hyperprogressive disease.[9] While previous studies have highlighted factors such as low TMB, reduced neoantigen presentation, and increased immunosuppressive cell populations like Tregs and MDSCs,[13, 14, 15] these explanations fail to fully account for the profound immune resistance observed in EGFR‐mutant tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.